1. Does your trust/HB have access to PET-CT for the investigation of suspected biochemical recurrence in prostate cancer patients?
a. Yes
b. Not on site, but we refer patients elsewhere (please state the trust/HB patients are referred to, if possible:)
c. No
2. If you answered “No” to question 1. Would you use PET-CT for the investigation of suspected biochemical recurrence in prostate cancer patients if it were available?
a. Yes
b. No
c. N/A – We already have access to PET-CT.
3. In 2020-21, how many patients do you estimate were investigated for suspected biochemical recurrence of prostate cancer at your trust/HB?
4. What percentage of patients with suspected biochemical recurrence do you estimate are referred for PET-CT at your trust/HB?
5. Of patients with suspected biochemical recurrence referred for PET-CT, what % of scans do you estimate use a PSMA tracer (either Ga-PSMA or F-PSMA)?
6. Are there any exclusion criteria for referral for PET-CT for suspected biochemical recurrence of prostate cancer? If so, what are they? E.g. Upper and lower PSA limits, age, life expectancy, ECOG score.
7. What do you estimate is the average waiting time for the PET-CT scans for investigation of suspected biochemical recurrence of prostate cancer?
8. What do you estimate is the average time it takes to report PET-CT scans for investigation of suspected biochemical recurrence of prostate cancer?
